Skip to main content
Premium Trial:

Request an Annual Quote

Scripps Florida Spins Off Company Working on Non-coding RNA

NEW YORK (GenomeWeb News) – Scripps Florida Professor Claes Wahlstedt has founded a new firm, called cuRNA, that will develop therapeutics and possibly diagnostic biomarkers based on non-coding RNA technology licensed from the institute.
 
Wahlstedt’s lab at Scripps Florida, which is part of La Jolla, Calif.-based Scripps Research Institute, has been researching the technology, which has been shown to play a vital role in gene expression, according to Scripps. Wahlestedt recently published a paper in the journal Nature Medicine showing that a specialized form of non-coding RNA was directly linked to increased levels of amyloid plaque in the brains of Alzheimer’s disease patients.
 
“We have licensed a fairly broad patent with many different targets in major therapeutic areas that fall under the non-coding RNA umbrella including metabolic disease and cancer,” Wahlestedt said in a statement last week. “These things can be used in a number of important ways — to treat disease or as diagnostic markers or tools.”
 
Wahlestedt founded cuRNA in June along with Joe Collard, a South Florida business consultant. They have set up operations in the offices of another biosciences firm in Palm Beach Gardens, Fla.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.